Porte-Monnaie acquires shares in Gedea Biotech

 januari 5, 2018

Gedea Biotech develops an antibiotic-free, safe and effective treatment of vaginal fungal infections. Vaginal yeast infections are a major problem that affects about 75% of all women at some point in life. Gedea Biotech’s substance, GDA001, is a natural substance that has always been part of our environment. It acts by lowering the pH as well as providing a physical barrier protection and inhibiting biofilm formation. The first product will be a topical treatment of vaginal fungal infections.